Advertisement

Dysphagia

, Volume 25, Issue 4, pp 277–283 | Cite as

Oropharyngeal Dysphagia in Infants and Children with Infantile Pompe Disease

  • Harrison N. JonesEmail author
  • Carolyn W. Muller
  • Min Lin
  • Suhrad G. Banugaria
  • Laura E. Case
  • Jennifer S. Li
  • Gwendolyn O’Grady
  • James H. Heller
  • Priya S. Kishnani
Original Article

Abstract

Pompe disease is a rare genetic progressive neuromuscular disorder. The most severe form, infantile Pompe disease, has historically resulted in early mortality, most commonly due to cardiorespiratory failure. Treatment with enzyme replacement therapy (ERT) using alglucosidase alfa (Myozyme®) has extended the lifespan of individuals with this disease. With the introduction of ERT and the resultant improved survival, dysphagia is being encountered clinically with increasing regularity though systematic data remain unavailable. We retrospectively studied the oropharyngeal swallowing of 13 infants and children with Pompe disease using videofluoroscopy before initiation of ERT, allowing for baseline swallow function to be established in an untreated cohort. Dysphagia was present in all 13 subjects, even in a participant only 15 days old. Oral stage signs were present in 77%, most frequently a weak suck in 69%. Pharyngeal stage signs were present in 100%, including a pharyngeal swallow delay in 92% and pharyngeal residue in 77%. Airway invasion was present in 76.9% of subjects, including penetration in five (38.46%) and silent aspiration in an additional five (38.46%). No relationship in the relative involvement of swallowing, gross motor function, and cardiac disease appeared to be present.

Keywords

Infantile Pompe disease Oropharyngeal dysphagia Aspiration Glycogen storage disease type I Acid maltase deficiency Enzyme replacement therapy Deglutition Deglutition disorders 

Notes

Acknowledgments

We would like to thank the staff at the Duke Clinical Research Unit, Stephanie DeArmey, MHS, PA-C, and Joanne Mackey, RN, MSN, CPNP for the excellent care provided to these patients. This study was supported by grant RR024128 from the Duke Clinical Research Unit, National Center for Research Resources, National Institutes of Health.

Disclosures

LEC has received honoraria from Genzyme Corporation; has participated in research supported by Genzyme Corporation, PTC Therapeutics, the Leal Foundation, and Families of SMA; has been awarded grant support from the National Skeletal Muscle Research Center; and is a member of the Pompe Registry Board of Advisors. GOG has received honoraria from Genzyme Corporation for educational presentations related to hearing assessment in children. PSK has received research grant support and honoraria from Genzyme Corporation. PSK is a member of the Pompe Disease Registry Advisory Board for Genzyme Corporation. rhGAA, in the form of Genzyme’s product Myozyme®, has been approved by the US FDA and the European Union as therapy for Pompe disease. Duke University and inventors for the method of treatment and predecessors of the cell lines used to generate the enzyme (rhGAA) benefit financially pursuant to the University’s Policy on Inventions, Patents and Technology Transfer. HNJ, CWM, ML, SGB, JSL, and JAH have no conflicts of interest to report.

References

  1. 1.
    Hirschhorn R, Reuser AJ. Glycogen storage disease type II: acid alpha-glucosidase (acid maltase deficiency). In: Scriver CR, Beaudet A, Sly WS, Valle D, Childs B, Kinzler KW, et al., editors. The metabolic and molecular bases of inherited disease. New York: McGraw Hill; 2001. p. 3389–420.Google Scholar
  2. 2.
    Kishnani PS, Howell RR. Pompe disease in infants and children. J Pediatr. 2004;144:S35–43.CrossRefPubMedGoogle Scholar
  3. 3.
    Kishnani PS, Hwu WL, Mandel H, Nicolino M, Yong F, Corzo D. A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. J Pediatr. 2006;148:671–6.CrossRefPubMedGoogle Scholar
  4. 4.
    Koeberl DD, Kishnani PS, Chen YT. Glycogen storage disease Types I and II: treatment updates. J Inherit Metab Dis. 2007;30:159–64.CrossRefPubMedGoogle Scholar
  5. 5.
    Van den Hout HM, Hop W, van Diggelen OP, Smeitink JA, Smit GP, Poll-The BTT, et al. The natural course of infantile Pompe’s disease: 20 original cases compared with 133 cases from the literature. Pediatrics. 2003;112:332–40.CrossRefPubMedGoogle Scholar
  6. 6.
    Kishnani PS, Corzo D, Nicolino M, Byrne B, Mandel H, Hwu WL, et al. Recombinant human acid α-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology. 2007;68:99–109.CrossRefPubMedGoogle Scholar
  7. 7.
    Van den Hout JM, Kamphoven JH, Winkel LP, Arts WF, De Klerk JB, Loonen MC, et al. Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk. Pediatrics. 2004;113:448–57.CrossRefGoogle Scholar
  8. 8.
    Genzyme, Cambridge, MA, Myozyme® package insert available at http://www.myozyme.com/.
  9. 9.
    Amalfitano A, Bengur AR, Morse RP, Majure JM, Case LE, Veerling DL, et al. Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial. Genet Med. 2001;3:132–8.CrossRefPubMedGoogle Scholar
  10. 10.
    Kishnani PS, Nicolino M, Voit T, Rogers RC, Tsai AC, Waterson J, et al. Chinese hamster ovary cell-derived recombinant human acid α-glucosidase in infantile-onset Pompe disease. J Pediatr. 2006;149:89–97.CrossRefPubMedGoogle Scholar
  11. 11.
    Klinge L, Straub V, Neudorf U, Voit T. Enzyme replacement therapy in classical infantile Pompe disease: results of a 10-month follow-up study. Neuropediatrics. 2005;36:6–11.CrossRefPubMedGoogle Scholar
  12. 12.
    Klinge L, Straub V, Neudorf U, Schaper J, Bosbach T, Görlinger K, et al. Safety and efficacy of recombinant acid alpha-glucosidase (rhGAA) in patients with classical infantile Pompe disease: results of a phase II clinical trial. Neuromuscul Disord. 2005;15:24–31.CrossRefPubMedGoogle Scholar
  13. 13.
    Nicolino M, Byrne B, Wraith JE, Leslie N, Mandel H, Freyer DR, et al. Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease. Genet Med. 2009;11:210–9.CrossRefPubMedGoogle Scholar
  14. 14.
    Rossi M, Parenti G, Della Casa R, Romano A, Mansi G, Agovino T, et al. Long-term enzyme1 replacement therapy for Pompe disease with recombinant human alpha-glucosidase derived from Chinese hamster ovary cells. J Child Neurol. 2007;22:565–73.CrossRefPubMedGoogle Scholar
  15. 15.
    Van Den DH, Reuser AJ, Vulto AG, Loonen MC, Cromme-Dijkhuis A, Van der Ploeg AT. Recombinant human alpha-glucosidase from rabbit milk in Pompe patients. Lancet. 2000;356:397–8.CrossRefGoogle Scholar
  16. 16.
    Van den Hout JMP, Reuser AJJ, Klerk JBC, Arts WF, Smeitink JAM, Van der Ploeg AT. Enzyme therapy for Pompe disease with recombinant human alpha-glucosidase from rabbit milk. J Inherit Metab Dis. 2001;24:266–74.CrossRefPubMedGoogle Scholar
  17. 17.
    Case LE, Hanna R, Frush DP, Krishnamurthy V, DeArmey S, Mackey J, et al. Fractures in children with Pompe disease: a potential long-term complication. Pediatr Radiol. 2007;37:437–45.CrossRefPubMedGoogle Scholar
  18. 18.
    Kamphoven JH, de Ruiter MM, Winkel LP, Van den Hout HM, Bijman J, De Zeeuw CI, et al. Hearing loss in infantile Pompe’s disease and determination of underlying pathology in the knockout mouse. Neurobiol Dis. 2004;16:14–20.CrossRefPubMedGoogle Scholar
  19. 19.
    Ing RJ, Cook DR, Bengur RA, Williams EA, Eck J, Dear Gde L, et al. Anaesthetic management of infants with glycogen storage disease type II: a physiological approach. Paediatr Anaesth. 2004;14:514–9.CrossRefPubMedGoogle Scholar
  20. 20.
    Wang LY, Ross AK, Li JS, Dearmey SM, Mackey JF, Worden M, et al. Cardiac arrhythmias following anesthesia induction in infantile-onset Pompe disease: a case series. Paediatr Anaesth. 2007;17:738–48.CrossRefPubMedGoogle Scholar
  21. 21.
    Muller CS, Jones HN, O’Grady G, Suarez AH, Heller JH, Kishnani PS. Language and speech function in children with infantile Pompe disease. J Pediatr Neurol. 2009;7:147–56.Google Scholar
  22. 22.
    Kishnani PS, Steiner RD, Bali D, Berger K, Byrne BJ, Case LE, et al. Pompe disease diagnosis and management guideline. Genet Med. 2006;8:267–88.CrossRefPubMedGoogle Scholar
  23. 23.
    Piper MC, Darrah J. Motor assessment of the developing infant. Philadelphia: W. B. Saunders; 1994.Google Scholar
  24. 24.
    Russell DJ, Rosenbaum PL, Avery L, Lane M (2002) Gross Motor Function Measure (GMFM-66 and GMFM-88) user’s manual. Clinics in Developmental Medicine, No. 159. Mac Keith Press, LondonGoogle Scholar
  25. 25.
    Lang RM, Bierig M, Devereaux RB. Recommendations for chamber quantification: a report from the American Society of Echocardiography’s guidelines and standards committee and the chamber quantification writing group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005;18:1440–63.CrossRefPubMedGoogle Scholar
  26. 26.
    Foster BJ, Mackie AS, Mitsnefes M, Ali H, Mamber S, Colan S. A novel method of expressing left ventricular mass relative to body size in children. Circulation. 2008;117:2769–775.CrossRefPubMedGoogle Scholar
  27. 27.
    Williams S, Witherspoon K, Kavsak P, Patterson C, McBlain J. Pediatric feeding and swallowing problems: an interdisciplinary team approach. Can J Diet Pract Res. 2006;67:185–90.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Harrison N. Jones
    • 1
    Email author
  • Carolyn W. Muller
    • 1
  • Min Lin
    • 2
  • Suhrad G. Banugaria
    • 3
  • Laura E. Case
    • 4
  • Jennifer S. Li
    • 5
  • Gwendolyn O’Grady
    • 1
  • James H. Heller
    • 1
    • 3
  • Priya S. Kishnani
    • 3
  1. 1.Division of Speech Pathology and Audiology, Department of SurgeryDuke UniversityDurhamUSA
  2. 2.Department of Biostatistics and BioinformaticsDuke UniversityDurhamUSA
  3. 3.Division of Medical Genetics, Department of PediatricsDuke UniversityDurhamUSA
  4. 4.Division of Physical Therapy, Department of Community and Family MedicineDuke UniversityDurhamUSA
  5. 5.Division of Cardiology, Department of PediatricsDuke UniversityDurhamUSA

Personalised recommendations